Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Protagonist Therapeutics (NASDAQ:PTGX) announced U.S. FDA approval of ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and patients 12+ weighing ≥40 kg. Approval followed four Phase 3 studies (2,500 patients) showing high efficacy and favorable safety. Johnson & Johnson will commercialize ICOTYDE.

Approval triggers a $50 million milestone to Protagonist; the company is eligible for 6–10% royalties and up to $580 million additional milestones. A webcast and call are scheduled for March 18 at 8:30 am ET.

Positive

FDA approval of ICOTYDE for plaque psoriasis
$50M milestone payment triggered at approval
6–10% tiered royalties (7.25% weighted at $4B sales)
Phase 3 program: 2,500 patients across four studies
High efficacy: ~70% IGA 0/1 and 55% PASI90 at Week 16
First oral IL-23R targeted peptide; once-daily pill

Negative

Commercialization dependent on Johnson & Johnson partner
Royalty structure caps Protagonist gross margin at 6–10%
Label limited to patients ≥12 years and ≥40 kg

News Market Reaction – PTGX

-0.14%

40 alerts

-0.14% News Effect

+4.1% Peak Tracked

-10.8% Trough Tracked

-$9M Valuation Impact

$6.74B Market Cap

0.6x Rel. Volume

On the day this news was published, PTGX declined 0.14%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.1% during that session. Argus tracked a trough of -10.8% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $6.74B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 3 studies: 4 studies Patients in trials: 2,500 patients Approval milestone: $50 million +5 more

8 metrics

Phase 3 studies 4 studies ICONIC Phase 3 program supporting ICOTYDE approval

Patients in trials 2,500 patients Total across four Phase 3 plaque psoriasis studies

Approval milestone $50 million Payment to Protagonist triggered by FDA approval of ICOTYDE

Future milestones Up to $580 million Potential additional regulatory and sales milestone payments

Royalty range 6%–10% Tiered royalties on global net sales of ICOTYDE

Clear/almost clear skin ≈70% Head-to-head trials, IGA 0/1 at Week 16

PASI90 responders 55% Head-to-head trials, PASI90 at Week 16

Safety vs placebo 1.1% difference Adverse reaction rates within 1.1% of placebo through Week 16

Market Reality Check

Price: $103.67 Vol: Volume 799,160 versus 20-...

normal vol

$103.67 Last Close

Volume Volume 799,160 versus 20-day average 684,881 suggests modestly elevated trading interest ahead of this FDA approval. normal

Technical Shares at $97.23 are trading above the 200-day MA at $72.02 and sit within $2.08 of the 52-week high at $99.31.

Peers on Argus

PTGX was moving up with a 0.5% gain, while the momentum scanner did not flag any...

PTGX was moving up with a 0.5% gain, while the momentum scanner did not flag any peers moving in tandem, indicating a stock-specific reaction rather than a broad biotechnology move.

Previous Fda approval Reports

1 past event · Latest: Jul 21 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jul 21	NDA submission	Positive	-0.5%	NDA filed for icotrokinra with strong Phase 3 efficacy and safety data.

Pattern Detected

Past FDA-related icotrokinra news with positive fundamentals coincided with a modest negative move, indicating prior divergence between news quality and price reaction.

Recent Company History

Over the past six months, Protagonist has advanced multiple regulatory milestones. A prior Jul 21, 2025 icotrokinra NDA submission, supported by four Phase 3 trials, was tagged as FDA-related yet saw a small negative price move. More recently, rusfertide received FDA NDA acceptance with Priority Review and the company reiterated expectations for a U.S. ICOTYDE decision in 2026. Today’s full FDA approval for ICOTYDE builds directly on that NDA submission and earlier guidance.

Historical Comparison

-0.5% avg move · The only prior FDA-approval-tagged icotrokinra event on Jul 21, 2025 produced a -0.47% move despite ...

fda approval

-0.5%

Average Historical Move fda approval

The only prior FDA-approval-tagged icotrokinra event on Jul 21, 2025 produced a -0.47% move despite positive data; today’s full FDA approval represents the logical next step after that NDA submission.

Historically, icotrokinra progressed from NDA submission backed by four Phase 3 trials to today’s FDA approval for plaque psoriasis, reflecting a continuum from regulatory filing to first commercial authorization.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-08-06

The company has an effective S-3ASR shelf registration filed on 2025-08-06 that remains active through 2028-08-06, with 0 recorded takedowns so far, indicating available but unused capacity for potential future offerings.

Market Pulse Summary

This announcement delivers full U.S. FDA approval for ICOTYDE, supported by four Phase 3 trials in 2...

Analysis

This announcement delivers full U.S. FDA approval for ICOTYDE, supported by four Phase 3 trials in 2,500 patients and strong Week 16 efficacy metrics around 70% clear or almost clear skin and 55% PASI90. It also triggers a $50 million milestone and access to up to $580 million in future milestones plus 6%–10% royalties. Investors may watch Johnson & Johnson’s launch execution and upcoming rusfertide decisions as next key catalysts.

Key Terms

interleukin-23, il-23 receptor antagonist, psoriasis area and severity index, pasi90, +4 more

8 terms

interleukin-23 medical

"an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe"

A small immune signaling protein that acts like a messenger to turn on and sustain inflammation; it helps coordinate certain immune cells and is implicated in autoimmune and inflammatory diseases. Investors care because drugs that block or modulate this messenger can reduce disease symptoms and generate significant sales or clinical value, so changes in trial results, approvals, or safety data around interleukin-23 pathways can materially affect a company's prospects and stock price.

il-23 receptor antagonist medical

"icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment"

An IL-23 receptor antagonist is a drug that blocks the receptor on immune cells that responds to interleukin‑23, a chemical messenger that drives inflammation in certain autoimmune diseases. By stopping that signal—like cutting off a messenger to halt a neighborhood alarm—these drugs can reduce symptoms and slow disease activity. Investors care because clinical trial results, approvals, dosing convenience and patent position determine market size, revenue potential, and competitive risk.

psoriasis area and severity index medical

"achieved a Psoriasis Area and Severity Index (PASI)90 response at Week 16."

A psoriasis area and severity index (PASI) is a clinical score that measures how much of the body is affected by psoriasis and how severe the lesions are, combining area and intensity into a single number. Investors care because pharmaceutical trials often use changes in this score to show a drug works; larger, faster improvements can drive regulatory approval, higher sales forecasts and clearer market value — like measuring both the size and heat of a spreading fire when deciding how effective a new extinguisher is.

pasi90 medical

"achieved a Psoriasis Area and Severity Index (PASI)90 response at Week 16."

PASI90 is a measure used in clinical trials for psoriasis that shows a 90% improvement in the severity and skin area affected by the disease compared with a patient’s starting point. Think of it like a before-and-after photo where 90% of the visible rash and redness has cleared; for investors, a high PASI90 rate signals a drug’s strong effectiveness, which can drive regulatory approval, market demand, pricing power, and competitive advantage.

phase 3 medical

"supported by four phase 3 studies that met all primary endpoints"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

nda regulatory

"announced the submission of a New Drug Application (NDA) to the FDA for icotrokinra"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

systemic therapy medical

"who are candidates for systemic therapy or phototherapy."

Treatments that travel through the bloodstream or throughout the body to reach disease sites rather than targeting a single spot—think of a citywide water main delivering resources rather than a local hose. They include drugs given orally, by injection, or infusion and are commonly used for cancers, infections, and autoimmune diseases. Investors care because systemic therapies often address large patient populations, drive long-term drug sales, carry regulatory and safety risks, and shape competitive positioning and pricing in healthcare markets.

phototherapy medical

"who weigh at least 40 kg who are candidates for systemic therapy or phototherapy."

Phototherapy is a medical treatment that uses specific wavelengths of light to change biological processes in the body—like easing newborn jaundice, treating skin conditions, or improving mood in seasonal depression. Investors care because demand, regulatory approvals, device makers, and reimbursement rules determine how broadly the therapy is adopted; successful clinical results or new, easier-to-use devices can create business growth similar to a new tool that suddenly makes a common job faster and cheaper.

AI-generated analysis. Not financial advice.

03/18/2026 - 08:05 AM

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill

Approval supported by four phase 3 studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients

$50 million milestone payment triggered by FDA approval; Protagonist is eligible to receive 6 - 10% royalties on sales and up to $580 million in future milestone payments

Webcast and conference call to be held at 8:30 am ET on March 18

NEWARK, CA / ACCESS Newswire / March 18, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval for ICOTYDE^™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.

ICOTYDE will be commercialized by Johnson & Johnson under the license and collaboration agreement established in 2017 between Protagonist and Janssen Biotech, Inc., a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization.

FDA approval of ICOTYDE triggers a $50 million milestone payment to Protagonist. Protagonist is eligible to receive up to $580 million in potential additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales, corresponding to 7.25% on a weighted-average basis at $4 billion in annual sales, with the top royalty tier of 10% applying to sales above $4 billion.

"ICOTYDE offers a novel plaque psoriasis treatment that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill. The FDA approval of ICOTYDE reflects a successful culmination of years of groundbreaking research and clinical development that began over 13 years ago in our laboratories and demonstrates the strength of our peptide technology platform to generate innovative therapies," said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist Therapeutics. "I am incredibly proud of our team's dedication and commitment to addressing unmet medical needs and making a meaningful difference in the lives of patients."

"I would also like to congratulate Johnson & Johnson for maintaining a productive and seamless collaboration ongoing since 2017 as this novel medicine was advanced from discovery through development and finally to FDA approval," Patel continued. "We look forward to results from ongoing clinical studies evaluating ICOTYDE in additional IL-23-driven diseases, including psoriatic arthritis, ulcerative colitis, and Crohn's disease. With the pending FDA decision for rusfertide this year, and the financial resources for accelerating pipeline investment, we're confident this is the beginning of a multi-year product-driven growth cycle for Protagonist Therapeutics."

ICOTYDE was developed using Protagonist's proprietary peptide technology platform. The Company continues to invest in its discovery engine and development pipeline, with multiple programs moving towards proof-of-concept trials designed to produce therapeutics with clinically relevant competitive differentiation.

Clinical evidence summary
ICOTYDE met all primary endpoints and demonstrated a favorable safety profile across four Phase 3 studies including 2,500 patients. The approval is based on an unprecedented body of evidence from the ICONIC clinical development program, which simultaneously evaluated ICOTYDE in adults and adolescents, high impact sites such as scalp and genital PsO, and in duplicate head-to-head trials versus an active comparator. In the head-to-head studies, approximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved a Psoriasis Area and Severity Index (PASI)90 response at Week 16. Rates of adverse reactions for ICOTYDE treated patients were within 1.1% of placebo through Week 16 and no new safety signals were identified through Week 52.

Additional studies underway in other disease areas include: ICONIC-PsA 1 (NCT06878404) and ICONIC-PsA 2 (NCT06807424) in active psoriatic arthritis; ICONIC-UC (NCT071196748) in moderately to severely active ulcerative colitis; and ICONIC-CD (NCT7196722) in moderately to severely active Crohn's disease.

Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on March 18^th at 8:30 am ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13759426

The webcast link for the event can be found here:
https://viavid.webcasts.com/starthere.jsp?ei=1756753&tp_key=f99979a28e

A replay will be available on the Company's Investor Relations Events and Presentations webpage following the event.

Unmet need in moderate to severe plaque psoriasis
Psoriasis affects more than eight million Americans, impacting physical comfort and quality of life, especially when lesions are on visible or sensitive areas. For many with moderate to severe disease, targeted systemic treatments are key. This aligns with International Psoriasis Council guidance to transition to systemic therapy if two cycles of topical medications applied for four weeks fail to bring meaningful improvement.

About ICOTYDE™ (icotrokinra)
ICOTYDE is the first and only targeted oral peptide designed to precisely block the IL-23 receptor, which underpins the inflammatory response in moderate to severe plaque PsO. ICOTYDE binds to the IL-23 receptor with high affinity and demonstrated potent inhibition of IL-23 signaling in human T cells. Clinical significance of these findings are unknown.

ICOTYDE is currently approved in the U.S. for the treatment of adults, and pediatric patients 12 years of age and older who weigh at least 40 kg, with moderate to severe plaque PsO who are candidates for systemic therapy or phototherapy. Patients on ICOTYDE take one pill, once a day with water upon waking, 30 minutes prior to eating food.

ICOTYDE is also currently in Phase 3 studies for active psoriatic arthritis, moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease.

FullICOTYDE^™ prescribing information will be available on the ICOTYDE^™ website.

About Plaque Psoriasis
Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease. Nearly one-quarter of all people with plaque PsO have cases that are considered moderate to severe. On Caucasian skin, plaques typically appear as raised, red patches covered with a silvery white buildup of dead skin cells or scale. On skin of color, the plaques may appear darker and thicker, and more of a purple, gray, or dark brown color. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso. Living with plaque PsO can be a challenge and impact life beyond a person's physical health, including emotional health, relationships, and handling the stressors of life. Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE^™ (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc.,a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of ICOTYDE and potential revenue from the Company's collaboration with Johnson & Johnson. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

FAQ

What did Protagonist (PTGX) announce on March 18, 2026 about ICOTYDE?

ICOTYDE received U.S. FDA approval for moderate-to-severe plaque psoriasis in eligible patients. According to Protagonist, approval followed four Phase 3 trials with 2,500 patients showing favorable efficacy and safety, and Johnson & Johnson will commercialize the medicine under the 2017 collaboration.

How much cash did Protagonist (PTGX) receive after FDA approved ICOTYDE?

Protagonist triggered a $50 million milestone payment upon FDA approval. According to Protagonist, the company is also eligible for up to $580 million more in regulatory and sales milestones plus tiered royalties on global net sales.

What royalties will Protagonist (PTGX) earn from ICOTYDE if approved commercially?

Protagonist is eligible for tiered royalties ranging from 6% to 10% on global net sales. According to Protagonist, the weighted-average royalty equals 7.25% at $4 billion in annual sales with 10% applying above $4 billion.

What were the key Phase 3 efficacy and safety results for ICOTYDE (PTGX)?

In head-to-head trials roughly 70% achieved IGA 0/1 and 55% reached PASI90 at Week 16. According to Protagonist, adverse reaction rates were within 1.1% of placebo through Week 16 and no new safety signals through Week 52.

When and how can investors access Protagonist's March 18, 2026 webcast and call?

Protagonist will host a webcast and conference call on March 18 at 8:30 am ET for an investor update. According to Protagonist, U.S. and international dial-in numbers and a webcast link are provided for live participation and a replay will be posted later.

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis